Moderna stock forecast 2025： MRNA is worth buying for 5 reasons

Moderna was founded in 2009 and was established in Cambridge, Massachusetts, USA. Its main business is genetic engineering and focuses on the research and development of mRNA-derived drugs.

The full name of mRNA is messenger RNA, pre-messenger RNA, a kind of immature single-stranded messenger ribonucleic acid, once it is completely processed, it is called "mature messenger RNA", or "mRNA".

These drugs use mRNA as a treatment method and use mRNA as the basis to inject the developed synthetic mRNA into the patient's body so that the patient's own cells can obtain the ability to treat themselves.

At present, the new crown vaccine being researched and developed by Moderna has an effective rate of 94.5%, so it has become one of the vaccines that are sold in large quantities all over the world.

Cambridge, Massachusetts, is not only home to Harvard University but also a world-renowned hot spot for modern biomedicine.

Despite such a "gorgeous background", Moderna's entrepreneurial road is not smooth.

Between 2010 and 2016, this company carried out a series of research and development for conventional vaccines, in an attempt to occupy this vast market and lucrative field with new vaccines.

However, these R&D and clinical trials have basically failed.

However, in this process of innovation, Modena established a leading position in the mRNA field, which attracted the attention of many pharmaceutical companies.

In 2013, Moderna entered the field of therapeutic vaccines in cooperation with AstraZeneca.

In 2014, Moderna joined forces with Alexion to enter the field of rare diseases.

Unfortunately, these cooperative studies have yet to yield results.

This makes some experts directly question the true reliability of Moderna's technology.

However, the outbreak of the new crown epidemic in 2020 gave Moderna an opportunity.

The effective rate of the new crown vaccine and the recent announcement of the clinical results of their therapeutic tumor vaccine has caused the stock price to rise sharply.

From January 1, 2020, to January 25, 2021, Moderna's stock has risen 690%.

Regarding Moderna's financial situation.

In May of this year, Moderna made a profit for the first time, with revenue of US$1.9 billion in the first quarter, and the new crown vaccine contributed nearly 90%.

Company valuation: it is still at a loss stage, and the price-earnings ratio does not exist;

P/B ratio = 23.01

Price-to-earnings ratio = price per share/earnings per share, it is one of the important indicators to measure whether a stock has investment value.

Under normal circumstances, the lower the price-earnings ratio of a stock, the lower the profitability of the market price relative to the stock, indicating that the shorter the investment payback period, the smaller the investment risk, and the greater the investment value of the stock.

If the price-to-book ratio is negative, it means that the company is still at a loss-making stage, and the risk is high, and it is impossible to predict the payback period of the investment.

PS: The price-to-book ratio refers to the ratio between the market price and the net assets per share. The price-to-book ratio = price per share/net assets per share. The lower the ratio, the lower the risk.

On January 25, 2021, the company's market value was 57.5 billion U.S. dollars, which is a company with a large market value.

Moderna is worth buying mainly for 5 reasons:

First of all, mRNA technology is extremely original, and RNA vaccines have been developed. It is the first to verify that the use of RNA can produce vaccines, and it is difficult for new competitors to replicate in a short period.

Due to the relatively high technical threshold for the development of mRNA vaccines, there is currently no product on the market for mRNA vaccines other than Pfizer, and its industry maturity needs to be improved.

The research and development principle of this type of vaccine is to deliver mRNA carrying the genetic information of the virus's characteristic protein into the cell and activate the immune response through expression in the body, thereby producing effective antibodies.

The process of human immunity with mRNA vaccine mimics the process of virus invasion to a certain extent and can stimulate human cellular and humoral immune responses.

Therefore, mRNA vaccines have multiple advantages such as strong immune activity, short research and development cycle, and suitable for the prevention of sudden infectious diseases, and are considered by the industry to have breakthrough potential.

Second, the product pipeline is rich. In addition to the new crown vaccine that is already on the market, Moderna's research and development line also have 1 phase 3 clinical, 7 phase 2 clinical trials, and 5 phase 1 clinical pharmaceuticals.

Third, the current clinical phase 2 data of the Moderna cytomegalovirus vaccine is good, and it enters clinical phase 3. If successful, it will be the only one on the market.

Fourth, before the outbreak of the new crown epidemic, Moderna's mRNA vaccine has carried out multiple clinical studies in the field of preventive vaccines and therapeutic tumor vaccines, of which the fastest progress is still in the phase II clinical trial stage.

Therefore, in addition to the vaccine field, RNA technology is also at the forefront of cancer immunotherapy, especially drugs for ovarian cancer.

Fifth, the company is currently profitable.

However, Moderna is a growth company with very high stock volatility, so we must pay attention to the investment scale during the investment process.

Comments

Teladoc stock forecast 2025: Is it time to buy TDOC?

TDOC's performance exceeded expectations. Why did the performance decline after the announcement? Teladoc (TDOC) reported quarterly earnings of US$0.13 per share, which exceeded the consensus estimate of a loss of US$0.57 per share. In the same period last year, it had a loss of US$0.4 per share. The earnings of this financial report far exceeded expectations. In the last quarter, people expected this telemedicine service company to lose 0.25 US dollars per share, but the actual loss per share was 0.27 US dollars, which was not as good as expected at the time. In the past four quarters, TDOC exceeded expectations twice. The management stated that the company's current momentum in various channels and regions should not be underestimated in the conference call. It has raised its annual revenue guidance to 20 million U.S. dollars, which is expected to be between 1.97 billion and 2.02 billion U.S. dollars. In the first quarter, the comp...

NIO stock forecast 2025: 2021 Q1 report analysis

April 30, NIO announced the first quarter of the 2021 financial report. Revenue reached 7.98 billion yuan, a year-on-year increase of 481.8%, and a month-on-month increase of 20.2%; gross profit was 1.5548 billion yuan, a month-on-month increase of 36.2%, and last year was -167.5 million yuan; a net loss of 350 million yuan was significantly narrowed year-on-year and month-on-month. Various indicators show that NIO's performance in the first quarter of this year is very impressive. Gross profit margin exceeds 20% for the first time NIO’s Q1 car sales were 7.40058 billion yuan, a year-on-year increase of 489.8% and a month-on-month increase of 20.0%. The gross profit margin of automobile sales was 21.2%, exceeding 20% for the first time, a significant increase from -7.4% in Q1 of 2020 and 17.2% in Q4 of 2020. In addition, Weilai's Q1 comprehensive gross profit margin in 2021 will also reach 19.5%. The founder, chairman, and CEO of NIO sai...

NVDA Stock Forecast and Analysis: 3 opportunities and 2 risks

What are the 3 opportunities and 2 risks for NVIDIA? How to invest in NVIDIA stock? NVIDIA(NVDA) stock buy or sell？ NVIDIA Stock Forecast and Analysis 2021 First, because in the third quarter of 2020, NVIDIA's revenue and profit have set record highs. Among them, revenue was 4.73 billion U.S. dollars, an increase of 57% year-on-year, and analysts expected it to be 4.41 billion U.S. dollars. NVIDIA's revenue Earnings per share were 2.91 US dollars, analysts expected to be 2.57 US dollars. It can be seen that both revenue and profit have exceeded analysts’ expectations. NVIDIA expects its fourth-quarter revenue to be US$4.8 billion, in line with analysts’ expectations of US$4.42 billion. Second, the current market value of NVIDIA is much higher than the combined market value of Intel and AMD. From the beginning of the year to now, NVIDIA has risen by 123%, AMD has risen by 87%, Intel has fallen by 24%, TSMC has risen by 64%, and the Nasdaq has risen by 33%. It can be seen that bo...

Capital Flows Tracking Weekly

Release: January 27, 2021 The weekly Capital Flows estimate the industry's total, based on the report covering more than 98% of mutual fund and ETF assets. Collect actual mutual fund net new cash flows and ETF net issuance together monthly; therefore, there is a discrepancy between these weekly estimates and monthly flows. The data from the previous few weeks reflect revisions due to data adjustments, reclassifications, and changes in the number of fund reports. Mutual fund data represents the estimated value of net new cash flows, that is, new sales minus redemptions plus net exchanges, while exchange-traded fund (ETF) data represents net issuance, that is, net issuance minus total Redemption amount. This series does not include data on mutual funds that primarily invest in other mutual funds and ETFs that primarily invest in other ETFs.

How to judge the market entry signal?

buy sell Most people lose money when investing in stocks. One of the biggest reasons is that they buy stocks at the wrong time. Why did they buy the stock at the wrong time? Facts have proved that many people do not know that stocks only rise 1/4 times, and that is the easiest time to make money. And in another 3/4 of the time, making money is difficult, and losing money is easier. Today, I will share how to choose the right time to buy stocks. I hope you can see the final result because, in the end, I will share with you how to use simple technical indicators to help us find the exact input time. First of all, everyone must know a concept, whether it is a stock market or a stock, there are four stages. Let us take the stock market as an example. The first stage is called the "next stage". At this time, the market has just experienced a sharp decline, and most investors in the market are not interested in the stock market, because their memories are still stuck in t...

BABA stock forecast 2025: The failure of Ant Financial's IPO

Ant Financial’s IPO was canceled, causing Alibaba’s share price to fall, Alibaba has been unfavorable this year. First, the cancellation of Ant Financial's IPO indirectly caused Alibaba's stock price to fall, and now there is an antitrust investigation led by Alibaba, which caused Alibaba's stock price to plummet by 15% in a single day. From the highest point in October, the stock price of 319 dollars has fallen by as much as 30% to 222 dollars. From the perspective of K-line, Alibaba has reached the Oversold area, and it will rebound upward in the short term. From the perspective of valuation, Alibaba’s valuation is as high as US$388, which is 74% of the current share price of US$222. Value-added space, so it seems that whether it is viewed from the short-term K-line or the long-term valuation, now is a good time to buy the bottom of Alibaba. Before investing, I will analyze and analyze the root cause of the disadvantage of Alibaba this time, because if this problem is not...

C3.ai stock forecast 2025: Is it time to buy now?

Few emerging technologies are as exciting as artificial intelligence. We have witnessed its ability to be applied in new ways, from quickly analyzing large amounts of data to improve the efficiency of hardware and software. C3.ai(AI) is one of the only companies in the world that develop artificial intelligence into independent services. In short, artificial intelligence is its entire business. Investors avoided such stocks this year because large technology companies began to engage in artificial intelligence projects, raising concerns about increased competitive threats. However, C3.ai continued to increase revenue, narrowed its losses, and added 82% of its customers in the fourth quarter of fiscal 2021. Therefore, the stock price has fallen about 60% so far this year, which may be a huge opportunity for those who want to get involved in this field. A unique business case Imagine that if a company needs to develop its own artificial intelligence, sim...

3 Chinese technology stocks forecast 2025: JD PDD and BZUN

Forget Alibaba（BABA)! These 3 Chinese technology stocks are more worth buying 　　 Hello everyone, Alibaba is China's largest e-commerce and cloud company. From January to late May, Alibaba's market value has shrunk by nearly 10%, lagging behind many peers. Antitrust investigations in China, stricter auditing standards in the United States, and funding from growth stocks to value stocks have all dragged down Alibaba's stock price. 　　 Alibaba’s stock is trading at an expected price-to-earnings ratio of 18 times, which may seem cheap, but analysts still expect Alibaba’s earnings to fall by 3% this year because it has absorbed a record US$2.75 billion in antitrust fines. It also needs to stop exclusive deals with big brands, which may weaken the company's defenses against smaller e-commerce markets. 　　 But this is not all. Alibaba may be forced to divest media assets and share user data with the government, and the group's financial technology su...

What is the average cost method?

Due to the recent plunge in the global market, I noticed that some people came out to promote an investment method called the fool-style stock disaster investment method. The thinking behind it is similar to other lazy investment methods, or monthly stocks/funds, just to change the saying, I will dismantle the problems behind you one by one. Let you see the risks you need to bear, first look at the logic behind this method. Its approach is this when the market drops 10%, you invest 20% of the funds to buy stock market ETFs when the market drops 20%, you invest another 20% when the market drops 30%, you invest another 20%, And so on. Until the market drops by 50%, you will put all the funds into the market, and when your average cost is equal to the market drops by 30%, you will buy all the funds in the market ETF (that is, All in). It is a kind of average cost method. The principle of this method is that, first, he believes that the maximum decline in the market is about 50%. A...

The thinking of value investing

value investing The epidemic continues to spread, the population of new crown infections keeps growing, and the world's economy is facing a huge cold winter. During this period, the death of black people in the United States even changed from anti-epidemic to protest, and economic and social life has always been difficult to return to the right track. But what is surprising is that the US Nasdaq index has gone out of the V-shaped reversal in just over two months, hitting a record high. Looking at the record, some customers left the market in the stage of the world epic plunge in mid-March, and recently reluctantly added the position back, the difference between the previous one and the next 10-15%, this is almost a return The average return of a good fund manager in a year. Sometimes, we always take a look at ourselves, thinking that we can sell high and sell low to make a difference, and even straighten the stock index line, but in the end, it is a fierce operation, al...

FinanceLinkway

Search This Blog